a. Induction protocol (Hans Van Vlierberghe) : The induction study in chronic hepatitis C assessing the interest of high and daily doses of interferon at the start of the treatment is published in the November issue of JOURNAL OF VIRAL HEPATITIS (Vol. 10, n°6, NOV, pp 460-466. ISSN: 1352-0504). You can find the abstract here.
A subgroup of this trial's population, the intravenous drug users, was studied for their compliance and response to treatment. You can find the abstract here (poster presented in Orlando).

b. Acute hepatitis C (Jean Delwaide) : the treatment is efficient: Alimen Pharmacol Ther 2004 Jul 1 ; 20(1): 15-22.

c. Study in non responders (Nadine Bourgeois) : This open trial assessed the efficiency of Roferon® + Copegus® + Amantan® in non responder patients (main coordinator : Nadine Bourgeois, with the support of Roche). One hundred patients were included. Twenty-nine percent of the treated patients became HCV-RNA negative, and 22% remained so at 24 weeks of follow-ip. This study has been presented at several meetings and at EASL meeting in Geneva, 2003. Find here the abstract of the poster and the full poster. J Hepatol 2003, 38, Suppl 2, 127.

d. Hepatitis C, naive patients : The randomized multicentre Belgian Trial comparing PegIntron® + Rebetol® versus Intron A® 3 x/w + Rebetol® versus Intron A® daily + Rebetol® (main coordinator : Yves Horsmans, with the support of Schering Plough) has been prematurely stopped in March 2002 after the inclusion of 330 patients. The decision to stop the study was unilaterally taken by Schering Plough. Nevertheless, the results have been presented during the Belgian Week of Gastroenterology, 2003 and 2004. A poster has been presented during the DDW 2003. Acta Gastroenterol Belg 67,D19, 2004.

e. Hepatitis C, relapsing patients : The BERNAR I study (main coordinator : Frederik Nevens, supported by Roche) comparing Pegasys® + Copegus® versus Roferon A® + Copegus® has been closed. Four hundred eighty patients (naive and relapsers) were included in the trial, but the BASL implication is only in the group of relapsers (around 100 patients). In patients with chronic hepatitis C relapsing after standard IFN-based therapy, PegIFN alfa2a once-weekly plus ribavirin provides similar reponse rates as in naïve patients. Oral presentation at the Belgian Week of Gastroenterology 2005: Acta Gastroenterol Belg 2005; 68:A27. J Hepatol 2005,42, Suppl 2, 215.

f. HIDA 2 Study : concerning the subgroup of drug users (main coordinator Geert Robaeys, supported by Schering-Plough), a poster has been presented at the EASL meeting (Geneva, July 2003). Closed Jan. 31, 2004.

g. Hepatitis C, HCV and HIV coinfection. This study was launched in 2002 under the coordination of P. Michielsen and Y. Horsmans with the support of Schering Plough. It was an open study assessing the efficacy of PegIntron® and Rebetol® for patients coinfected by HIV and HCV viruses. Closed Dec. 31, 2003.

h. Hepatitis C, non responders. The BETTY study compared Pegasys® + Copegus® + Amantan® versus Roferon® + Copegus® + Amantan® in non responders. This study was coordinated by N. Bourgeois and supported by Roche. Closed May 19, 2004.

i. Hepatitis C, hemophiliacs

The inclusion period is closed since Feb. 2008- please don't forget to include your cases !